MedTrace Logo

Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

NCT02163473 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2016-10-13

No results posted yet for this study

Summary

The purpose of this research study is to determine if a chemical marker in the blood, hypoxia-inducible factor (HIF-1 alpha), can be used to predict subject's hospital outcomes when the subject is diagnosed with sepsis. Sepsis is defined as either the presence of pathogenic organisms or their toxins in the blood and tissues. Sepsis is one of the most significant challenges in critical care medicine. The investigators propose that hypoxia-induced expression of HIF-1 alpha will correlate with the clinical features of Sepsis and in the future, HIF-1 alpha may be used as a biomarker in Sepsis.

Conditions

Interventions

PROCEDURE

Septic patients

The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.

PROCEDURE

Healthy Control

The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Wael Nasser, MD · University of Florida

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02163473 on ClinicalTrials.gov